Longboard Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)
Buy Rating Affirmed for Longboard Pharmaceuticals Amidst Positive Clinical Progress and Market Potential for Bexicaserin
Longboard Pharmaceuticals Analyst Ratings
Longboard Pharmaceuticals (LBPH) Receives a Buy From Wedbush
Longboard Pharmaceuticals Analyst Ratings
Buy Rating Affirmed on Longboard Pharmaceuticals With Promising Bexicaserin Developments and Regulatory Milestones Ahead
Longboard Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Laboratory (LH) and Longboard Pharmaceuticals (LBPH)
Longboard Pharmaceuticals Analyst Ratings
Analysts' Top Healthcare Picks: Longboard Pharmaceuticals (LBPH), Phathom Pharmaceuticals (PHAT)
Longboard Pharmaceuticals Analyst Ratings
Longboard Pharmaceuticals Analyst Ratings
Buy Rating Affirmed: Longboard Pharmaceuticals' Bexicaserin Shows Promising Efficacy and Strategic Milestones
Longboard Stock up 8% as Citi Initiates at Buy, Citing Takeover Potential
Longboard Pharmaceuticals Analyst Ratings
Longboard Pharmaceuticals Analyst Ratings
B. Riley Raises Price Target on Longboard Pharmaceuticals to $30 From $13, Maintains Buy Rating
Longboard Pharmaceuticals (LBPH) Receives a Buy From Wedbush
HC Wainwright & Co. Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $60
No Data